Autoantibodies Which Bind to and Activate Keratinocytes in Systemic Sclerosis

Cells. 2023 Oct 20;12(20):2490. doi: 10.3390/cells12202490.

Abstract

Systemic sclerosis (SSc) is a multisystem connective tissue disease characterised by pathological processes involving autoimmunity, vasculopathy and resultant extensive skin and organ fibrosis. Recent studies have demonstrated activation and aberrant wound healing responses in the epithelial layer of the skin in this disease, implicating the epithelial keratinocytes as a source of pro-fibrotic and inflammatory mediators. In this paper, we investigated the role of Immunoglobulin G (IgG) autoantibodies directed against epithelial cells, as potential initiators and propagators of pathological keratocyte activation and the ensuing SSc fibrotic cascade. A keratinocyte cell-based ELISA is used to evaluate the binding of SSc IgG. SSc skin biopsies were stained by immunofluorescence for the presence of IgG in the keratinocyte layer. Moreover, IgG purified from SSc sera was evaluated for the potential to activate keratinocytes in tissue culture and to induce TLR2 and 3 signalling in reporter cell lines. We demonstrate enhanced binding of SSc IgG to keratinocytes and the activation of these cells leading to the release of IL-1α, representing a potential initiating pathway in this disease.

Keywords: autoantibody; epithelial cell; fibrosis; scleroderma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies*
  • Fibrosis
  • Humans
  • Immunoglobulin G / metabolism
  • Keratinocytes / metabolism
  • Scleroderma, Systemic* / pathology

Substances

  • Autoantibodies
  • Immunoglobulin G

Grants and funding

Funding for the study was provided by the Rosetrees Trust, “Treating Scleroderma” #M429-F1, and by The Peltz Trust at the Prism Fund, “Investigating novel treatments for connective tissue disorders”, The Royal Free Charity, “Scleroderma Research”.